Clinical Trials Logo

Lung Neoplasms clinical trials

View clinical trials related to Lung Neoplasms.

Filter by:

NCT ID: NCT05288569 Recruiting - Lung Cancer Clinical Trials

irAE Prediction of Anti-PD-1/L1 in Lung Cancer

Start date: January 21, 2022
Phase:
Study type: Observational

the purpose of this study is to identify multi-dimensional immunological biomarkers including cytokines, autoantibodies, and immune cell subtypes of immune-related adverse events (primary) and prognosis(secondary) in the anti-PD-1/anti-PD-L1 immunotherapy for lung cancer

NCT ID: NCT05287386 Recruiting - Clinical trials for Advanced Non-Small Cell Lung Cancer

A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy

Start date: January 21, 2022
Phase: Phase 2
Study type: Interventional

This study is a prospective single-arm phase II clinical study. Advanced non-small cell lung cancer patients with FGFR 1-3 alterations (including but not limited to FGFR amplification, rearrangement/fusion, mutation, etc.) who have failed standard therapy will be enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligible in screening.

NCT ID: NCT05284994 Recruiting - Clinical trials for Nonsmall-cell Lung Cancer

TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer

Start date: March 11, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

TQ-B3525 tablet is a new α/δ dual inhibitor phosphatidylinositol 3-kinase inhibitor developed by Chia Tai Tianqing pharmaceutical Group Co., Ltd. It can overcome the drug resistance problem caused by the up-regulation of phosphatidylinositol 3-kinase α subunit activity caused by the single inhibition of phosphatidylinositol 3-kinase δ subunit. This study is a single-arm, open-label, multi-cohort, multi-center clinical study of the safety and efficacy of TQ-B3525 tablets combined with osimertinib in subjects with advanced non-small cell lung cancer, aiming to evaluate TQ-B3525 tablets combined with osimertinib, the safety, tolerability, and efficacy of the treatment of patients with advanced non-small cell lung cancer who have failed epidermal growth factor receptor inhibitor therapy, while exploring the efficacy, resistance mechanism, and safety in the dose escalation phase biomarkers.

NCT ID: NCT05284539 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

Awesome
Start date: April 1, 2022
Phase: Phase 2
Study type: Interventional

The investigators want to evaluate the Efficay and Safety of Platinum-based Chemotherapy with or without immune checkpoint inhibitors for EGFR/ALK/ROS1 Positive NSCLC who Failed from First-Line Standard Treatment.

NCT ID: NCT05281237 Recruiting - Lung Cancer Clinical Trials

Avecure Flexible Microwave Ablation Probe For Lung Nodules

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size. This research study involves microwave ablation (MWA)

NCT ID: NCT05278052 Recruiting - Clinical trials for Oligometastatic Disease

Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC

TARGET-02
Start date: April 20, 2020
Phase: Phase 3
Study type: Interventional

Standard Maintenance Therapy versus Local Consolidative Radiation Therapy and standard maintenance therapy in 1-5 sites of OligoMetastatic Non-small cell lung cancer (NSCLC): A Phase III Randomized Controlled Trial

NCT ID: NCT05277844 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC

TARGET-01
Start date: November 11, 2019
Phase: Phase 2
Study type: Interventional

A Phase II randomized controlled trial of TKI Alone versus TKI and Local Consolidative Radiation Therapy in oncogene driver mutated oligo metastatic Non-small cell lung cancer patients.

NCT ID: NCT05276726 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

Start date: August 17, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation.

NCT ID: NCT05275868 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer

Start date: October 5, 2022
Phase: Phase 1
Study type: Interventional

Study of MGY825 single agent in adult patients with advanced non-small cell lung cancer.

NCT ID: NCT05274451 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study to Investigate LYL797 in Adults With Solid Tumors

Start date: March 29, 2022
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC). The first part of the study will determine the safe dose for the next part of the study, and will enroll TNBC and NSCLC patients. The second part of the study will test that dose in additional TNBC and NSCLC patients.